Article Text
Abstract
Objective: To determine the pattern of β blocker prescribing over one year in a heart failure clinic with a structured approach towards initiation and dose titration and to give a real life perspective on β blocker use, compliance, and target dose achievement.
Methods: Data were retrospectively analysed on 513 consecutive patients regularly attending a community heart failure clinic over a year. Systolic dysfunction was determined from two dimensional echocardiography (left ventricular ejection fraction ⩽ 40%) and lung function was assessed by spirometry. All patients were considered for β blocker initiation and dose up titration.
Results: Within one year 157 patients died. 143 patients started β blockers resulting in 315 (88%) patients taking β blockers at one year; 38% were taking the target dose. 124 had evidence of airways obstruction at baseline, 100 (81%) of whom were taking β blockers at one year. Forced expiratory volume in one second (1.1 v 1.5 l, p < 0.01) and forced vital capacity (2.3 v 2.5 l/min, p = 0.2) were not reduced in patients with airways obstruction who received β blockers. Daily doses of β blockers at one year did not differ statistically between patients with obstructive and patients with non-obstructive spirometry results. 12 patients discontinued β blockers and 14 required dose reduction due to side effects.
Conclusion: The majority of patients with heart failure and obstructive airways disease can safely tolerate low dose initiation and gradual up titration of β blockers.
- ACE, angiotensin converting enzyme
- CI, confidence interval
- COMET, carvedilol or metoprolol European trial
- COPD, chronic obstructive pulmonary disease
- COPERNICUS, carvedilol prospective randomised cumulative survival
- FEV1, forced expiratory volume in one second
- FVC, forced vital capacity
- IMPACT-HF, initiation management predischarge process for assessment of carvedilol therapy for heart failure
- MERIT-HF, metoprolol CR/XL randomised intervention trial in congestive heart failure
- NYHA, New York Heart Association
- OR, odds ratio
- heart failure
- β blockers
- chronic obstructive pulmonary disease
Statistics from Altmetric.com
- ACE, angiotensin converting enzyme
- CI, confidence interval
- COMET, carvedilol or metoprolol European trial
- COPD, chronic obstructive pulmonary disease
- COPERNICUS, carvedilol prospective randomised cumulative survival
- FEV1, forced expiratory volume in one second
- FVC, forced vital capacity
- IMPACT-HF, initiation management predischarge process for assessment of carvedilol therapy for heart failure
- MERIT-HF, metoprolol CR/XL randomised intervention trial in congestive heart failure
- NYHA, New York Heart Association
- OR, odds ratio
Footnotes
-
Published Online First 10 June 2005
-
No competing interests (all authors)